Published in AIDS Weekly, March 10th, 1997
The planned studies include an evaluation of a new manufacturing process and a pilot study designed to enhance the detection of antiviral effects in patients receiving antiviral drug therapy. The announcement followed a report of preliminary results from the initial Phase II study of this therapy.
Dr. H. Clifford Lane, U.S. National Institute of Allergy and Infectious Diseases (NIAID), reported these data at the American Association of Asthma, Allergy, and Immunology/Clinical Immunology Society Conference,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.